Differences of blood cells, lymphocyte subsets and cytokines in COVID-19 patients with different clinical stages: a network meta-analysis

The coronavirus disease 2019 (COVID-19) is a pandemic disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a beta genus coronavirus that generally susceptible to humans. World Health Organization (WHO) COVID-19 Situation Report showed that up to June 8, 2020 more than 6,931,000 cases and 400,857 deaths were reported worldwide and there were 84, 634 total confirmed cases and 4645 deaths in China [1]. The patients with COVID-19 were classified into four groups based on the New Coronavirus Pneumonia Prevention and Control Program [2]: mild cases with mild clinical symptoms, and no pneumonia manifestation on imaging; moderate cases with any of fever, respiratory tract symptoms, and pneumonia manifestations in imaging; severe cases with respiratory rate ≥ 30 breath per minute, oxygen saturation ≤ 93% at rest state, arterial partial pressure of oxygen (PaO₂)/ Oxygen concentration (FiO₂) ≤ 300 mmHg and lung lesions progression > 50% manifestations in imaging within 24 to 48 h; and critical cases with any of respiratory failure requiring mechanical ventilation, shock, multiple organ failure requiring intensive care unit (ICU) treatment. These symptoms caused by COVID-19 infection were related to sustained responses of cytokines and chemokines (known as cytokine storm), which increased the incidence of immunity disorders and mortality [3].

Blood cells, lymphocytes, and cytokines levels can be used as important immune inflammatory parameters of adult patients with COVID-19 [4]. Lymphocytes and the subsets perform great roles in the maintenance of the function of the immune system. As with other infectious and immune diseases, viral infections can cause dysregulation of lymphocytes and their subsets [5]. T cells play a vital role in the clearance of the virus whereby CD3⁺ T cells and mature T cells activate CD4⁺ T cells and CD8⁺ T cells [6], cytotoxic T cells CD8⁺ produces molecules that eliminate the virus from the host [7], T helper cells (CD4⁺) help cytotoxic T cells and B cells (CD19⁺) to improve their capacity to clear pathogens [8]. Cytokines are small protein molecules such as IL-6, IL-10, and TNF-α secreted by T lymphocytes which play a great role in intercellular communications and immunomodulation function [9]. Although, continuous stimulation by the virus may cause T cells exhaustion a condition that may lead to a loss in cytokine production and decline in functions [10, 11] and multiple organ dysfunction [12].

Currently, most of the studies on immune inflammatory indicators in COVID-19 patients are single-centered and showed diverse results. Some studies have shown that compared with non-severe COVID-19, WBC, and NEUT in severe patients were significantly increased, while LYM was decreased [13‐15]. In addition, the total counts of LYM subsets such as CD3⁺ T cells, CD4⁺ T cells, CD8⁺ T cells, and CD19⁺ B cells were substantially lower to both severe and non-severe COVID-19 patients [15, 16]. Moreover, cytokines such as IL-6, IL-10, and TNF-α were revealed to increase with the severity of the diseases in COVID-19 patients [15, 17‐19]. A study by Zhu et al. confirmed the predictive value of immune-inflammation parameters that IL-6 played a pivotal role in the severity of COVID-19 and had a potential value for monitoring the process of severe cases [20]. However, some studies reported controversial results that the level of WBC in severe patients was lower than the mild [21‐23], but the LYM tended to increase with the deterioration of the disease [4, 24, 25]. Furthermore, studies focusing on immune inflammatory parameters of COVID-19 patients with different clinical stages rarely consider whether the severity of the disease varies in each age group. In addition, there is still a controversy on how their inflammation parameters change.

In the presence of this rapidly emerging novel infectious disease, it is necessary to identify immune inflammatory parameters that could predict the disease severity and the prognosis essentially for guiding clinical care. Therefore, we categorized COVID-19 patients into mild, severe, and critical groups as well as performed network meta-analysis to compare the difference in the blood cells, lymphocyte subsets, and cytokines at different clinical stages.

In this study, we systematically reviewed the available evidence and conducted a network meta-analysis to describe the differences in the blood cell, lymphocyte subsets, and cytokine levels in patients suffered from COVID-19 at different clinical stages. Our results showed that with the severity of COVID-19 worsens, the count of WBC, NEUT, IL-6, and IL-10 increased significantly, while LYM levels decreased. Compared with the mild group, the levels of PLT, CD3⁺ T cells, CD4⁺ T cells, CD8⁺ T cells, and CD19⁺ B cells were significantly decreased in the severe and critical patients. IL-1β was significantly increased in critically ill patients.

Our results were consistent with most studies focusing on immune inflammatory parameters abnormalities in COVID-19 patients, documented the higher WBC and NEUT count in the severe group than in the non-severe group [18, 30‐32]. With the aggravation of the disease, COVID-19 patients are susceptible to bacterial and fungal infections due to low autoimmunity, and the increase in WBC and NEUT counts reflecting their inflammation levels are higher than those of the mild patients [33]. The increase in NEUT counts may be associated with cytokine storms caused by viral invasion [30]. LYM decrease was associated with the increase in the disease severity in COVID-19 patients. The possible mechanism of LYM reduction was that the virus attacks target cells, directly damage cells, and the viral infection caused non-specific damage, immune cells enter the activated state and participate in the antiviral process, leading to severe injury and apoptosis. Therefore, it can be considered that the supplement of LYM may be the key to the recovery of COVID-19 patients [34].

In our study, we found that LYM was reduced in COVID-19 patients, especially in the critically ill group. Typical T lymphocytes (CD3⁺) were mainly reduced, while no significant variation was observed in NK cells (CD16⁺ CD56⁺), which have been confirmed in other studies [33, 35]. LYM subsets are essential for maintaining immune system function and eliminating viruses and are often altered after viral infection. The SARS-CoV, MERS-CoV, and SARS-CoV-2 of the coronavirus family may all cause a decrease in the count of LYM and its subset of infected patients [19], which may be due to the homology, similar genes, viral structure, and pathogenesis among the three [36]. At present, limited autopsy and pathological findings have found that the spleen, lymph nodes, and other lymphoid tissues of COVID-19 infected patients were necrotic, and lymphocyte infiltration was observed in alveolar septum [33], presumably be caused by direct virus attack or immune injury mediated by it. Isolation of lymphocytes in the lung may be another potential cause, but the specific mechanism needs to be further explored.

Meanwhile, as the severity of COVID-19 worsens, the concentrations of inflammatory cytokines are getting higher. A recently published meta-analysis showed that IL-6 levels in patients with severe COVID-19 were higher than those in non-severe COVID-19 patients (MD: 38.6 ng/L, 95% CI: 24.3–52.9 ng/L) [37], the trend of difference was consistent with our study. In many cases, elevated IL-6 has been demonstrated to have different degrees of inflammation [38]. The pathophysiological characteristics of COVID-19 are severe inflammation and chemokine storms, which may be the driving factors behind acute lung injury and acute respiratory distress syndrome [39], as well as the main consequence of IL-6 elevation [30, 40]. Mild patients had slightly higher cytokine levels or were in the normal range, which means there was no excessive inflammatory response in the body. However, serum levels of various cytokines in critical patients were significantly elevated, suggesting that the body is in an over-immune state during the progression of the disease, a large number of inflammatory cells and inflammatory mediators have been released in critical patients [39, 41].

Our quantitative analysis results were consistent with most of the published research papers, but we were also aware of some inconsistencies. We found that the number of COVID-19 patients included in some studies was small, and the sample size distributions of the three groups were greatly varied. In addition, the age of the patients in the severe group was generally higher than that in the mild group, which is in line with the real world. For example, there were 12 cases in the study of Liu et al., among which only 3 patients had critical symptoms [42]. Moreover, a study by Xiao et al. [21], accounted for higher weight in our network meta-analysis due to the large sample size. However, the average age of the study subjects was relatively young, and the proportion of the critical group was less than 9% of the total patients, which may explain the inconsistency.

To the best of our knowledge, this is the first network meta-analysis that systematically reviewed the differences in blood cells, lymphocyte subsets, and cytokine levels among COVID-19 patients with different clinical stages. First, we completed the comparisons of immune inflammatory parameters between any two groups among the mild, severe, and critical patients. Most of the included studies were divided into mild and severe groups, but our analysis of the critical cases was not limited, which was difficult to accomplish in the conventional meta-analysis. In addition, we analyzed as many immune-related cells and cytokines as possible to demonstrate potential relationships and differences. Importantly, we found that patients who were above-average age had a higher proportion of critical events and stronger changes in their immune inflammatory parameters. It is worth mentioning that the total number of patients included in the network meta-analysis was large, and the effect value of the pooled analysis was stable, so the results can be considered reliable and powerful. Some limitations of our studies should be noted. Firstly, the included studies were cross-sectional study and the cases were hospitalized cases, no further conditions of the patients were reported. Secondly, the mean age of the patients in each study varied widely, and subjects of different age groups have varied physical conditions, which may also affect the changes of immune inflammatory parameters during illness. Besides, the sample size of some studies was small, which may reduce the power of the studies. Ultimately, most of the studies included were performed in China, and measurements may be varied across laboratories.

The immune suppression and inflammatory injury play crucial roles in the progression of COVID-19, and the identification of susceptible cells and cytokines can also guide the development of accurate treatment plans for patients with different clinical stages. The results reminded us to emphasize the cytokine storm in the progression of COVID-19. In the future, large-scale, long-term research should be devoted to confirm the results of our network meta-analysis, identify other immune inflammatory parameters of COVID-19 serious infection or poor prognosis, and clarify the underlying mechanisms of their relationship.